Trevi Therapeutics, Inc. TRVI Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $18.91M-44.5% | $34.1M+5.2% | $32.4M+157% | $12.59M-65.8% | ||
| $169.35M+130% | $73.53M+45.4% | $50.57M-53.1% | $107.92M— | ||
| $1.26M+34.5% | $939K-74.1% | $3.62M+355% | $795K-10.3% | ||
| $191.66M+75.1% | $109.43M+25.0% | $87.55M-28.6% | $122.62M+223% | ||
| $178K+13.4% | $157K-27.3% | $216K+27.1% | $170K+221% | ||
| $677K-26.0% | $915K-19.5% | $1.14M+4,638% | $24K-81.7% | ||
| $928K+282% | $243K-18.2% | $297K+44.9% | $205K-38.6% | ||
| $193.44M+74.4% | $110.9M+24.0% | $89.4M-27.3% | $123.02M+220% | ||
| $3.91M+14.6% | $3.41M+88.7% | $1.81M-36.7% | $2.86M+0.3% | ||
| $5.53M-18.8% | $6.81M+83.6% | $3.71M+5.4% | $3.52M-7.6% | ||
| $307K+20.9% | $254K+38.0% | $184K+636% | $25K-79.2% | ||
| $9.75M-7.2% | $10.51M+80.4% | $5.82M-56.5% | $13.4M+5.3% | ||
| $446K-40.3% | $747K-25.4% | $1M+49,950% | $2K-91.7% | ||
| $10.2M-9.4% | $11.26M+64.2% | $6.86M-55.9% | $15.56M-27.3% | ||
| —— | —— | —— | —— | ||
| $128K+36.2% | $94K+38.2% | $68K+13.3% | $60K+107% | ||
| $512.77M+32.7% | $386.53M+20.2% | $321.64M+1.3% | $317.59M+60.4% | ||
| -$329.8M-14.9% | -$287.05M-20.0% | -$239.13M-13.8% | -$210.07M-16.1% | ||
| $148K+143% | $61K+310% | -$29K+76.2% | -$122K— | ||
| $183.24M+83.9% | $99.64M+20.7% | $82.55M-23.2% | $107.46M+529% | ||
| $193.44M+74.4% | $110.9M+24.0% | $89.4M-27.3% | $123.02M+220% | ||
| $169.35M+130% | $73.53M+45.4% | $50.57M-53.1% | $107.92M— | ||
| $2.13M+146% | $867K-9.2% | $955K-27.2% | $1.31M+444% | ||
| $928K+282% | $243K-18.2% | $297K+44.9% | $205K-38.6% | ||
| $677K-26.0% | $915K-19.5% | $1.14M+4,638% | $24K-81.7% | ||
| $677K-26.0% | $915K-19.5% | $1.14M+4,638% | $24K-81.7% | ||
| $928K+282% | $243K-18.2% | $297K+44.9% | $205K-38.6% | ||
| $677K-26.0% | $915K-19.5% | $1.14M+4,638% | $24K-81.7% | ||
| $928K+282% | $243K-18.2% | $297K+44.9% | $205K-38.6% | ||
| $5.53M-18.8% | $6.81M+83.6% | $3.71M+5.4% | $3.52M-7.6% | ||
| $5.53M-18.8% | $6.81M+83.6% | $3.71M+5.4% | $3.52M-7.6% | ||
| $753K-29.2% | $1.06M-27.2% | $1.46M+5,307% | $27K-81.3% | ||
| $128K+36.2% | $94K+38.2% | $68K+13.3% | $60K+107% | ||
| —— | —— | —— | $2.15M-75.1% | ||
| $1.26M+34.5% | $939K-74.1% | $3.62M+355% | $795K-10.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Trevi Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 24.75 — current assets exceed current liabilities.
- Where does Trevi Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.